CN112136979A - 一种降低猪血脂的饲料预混剂及其制备方法和应用 - Google Patents
一种降低猪血脂的饲料预混剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN112136979A CN112136979A CN202010976984.2A CN202010976984A CN112136979A CN 112136979 A CN112136979 A CN 112136979A CN 202010976984 A CN202010976984 A CN 202010976984A CN 112136979 A CN112136979 A CN 112136979A
- Authority
- CN
- China
- Prior art keywords
- feed premix
- parts
- reducing
- blood fat
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 235000019197 fats Nutrition 0.000 claims abstract description 32
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- 241000219823 Medicago Species 0.000 claims abstract description 15
- 241000233866 Fungi Species 0.000 claims abstract description 13
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004380 Cholic acid Substances 0.000 claims abstract description 10
- 102000004882 Lipase Human genes 0.000 claims abstract description 10
- 108090001060 Lipase Proteins 0.000 claims abstract description 10
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 10
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 10
- 229960002471 cholic acid Drugs 0.000 claims abstract description 10
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004367 Lipase Substances 0.000 claims abstract description 9
- 235000019421 lipase Nutrition 0.000 claims abstract description 9
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 9
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 9
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 7
- 108010023302 HDL Cholesterol Proteins 0.000 claims abstract description 7
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 7
- 210000002966 serum Anatomy 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 5
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims abstract description 4
- 241000282887 Suidae Species 0.000 claims description 8
- 229940040461 lipase Drugs 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 235000000023 Auricularia auricula Nutrition 0.000 claims 1
- 241001149430 Auricularia auricula-judae Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100040423 Transcobalamin-2 Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
- A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Birds (AREA)
Abstract
本发明涉及饲料预混剂,尤其是涉及一种降低猪血脂的饲料预混剂及其制备方法和应用,每100重量份饲料预混剂份包括以下重量份含量的组分:苜蓿30‑45,亚油酸3‑8,黑木耳6‑12,合成胆酸0‑8,脂肪酶3‑8,谷氨酸钠0‑15,余量为载体。与现有技术相比,本发明原料易得,相对于使用药物控制血脂含量,本发明的预混剂通过功能性营养改善体内组成,安全无副作用;有利于降低血清总胆固醇、甘油三酯和低密度脂蛋白胆固醇的含量,增加高密度脂蛋白胆固醇的含量。
Description
技术领域
本发明涉及饲料预混剂,尤其是涉及一种降低猪血脂的饲料预混剂及其制备方法和应用。
背景技术
血脂广泛存在于动物体内,它们是细胞基础代谢的必需物质,与心血管疾病、肥胖、代谢综合征和糖尿病等密切相关。高血脂会引起猪体内脂肪代谢的障碍,影响猪对饲料中脂肪的利用,降低经济效益。目前有采用药物来降低猪血脂的方法,但是药物在饲料中的使用存在一定的风险,而且不能够长期使用。另外,人类对血脂问题越来越关注,以猪作为模型,可以很好的研究降低血脂的机理,为人类健康降低血脂提供参考。
发明内容
本发明的目的就是为了提供一种降低猪血脂的饲料预混剂及其制备方法和应用。本发明采用的是非药物性质的原料,原料易得,相对于使用药物控制血脂含量,本发明的预混剂通过功能性营养改善体内组成,安全无副作用,可以长期使用。有利于降低血清总胆固醇、甘油三酯和低密度脂蛋白胆固醇的含量,增加高密度脂蛋白胆固醇的含量。
本发明的目的可以通过以下技术方案来实现:
本发明第一方面提供一种降低猪血脂的饲料预混剂,每100重量份饲料预混剂份包括以下重量份含量的组分:
优选地,所述的载体为玉米芯载体。
优选地,所述的苜蓿采用一级苜蓿,蛋白含量20-22%。
优选地,所述的合成胆酸来源于山东龙昌动物保健品有限公司。
优选地,所述的脂肪酶来源于武汉新华扬生物股份有限公司。
优选地,所述的谷氨酸钠来源于河南省莲花味精集团有限公司。
本发明第二方面提供所述的降低猪血脂的饲料预混剂的制备方法,包括以下步骤:
(1)按配比称取苜蓿、亚油酸、黑木耳、合成胆酸、脂肪酶、谷氨酸钠和载体;
(2)将苜蓿及黑木耳干燥后粉碎,然后与亚油酸、合成胆酸、脂肪酶、谷氨酸钠和载体混合均匀,得到所述的降低猪血脂的饲料预混剂。
优选地,苜蓿及黑木耳干燥后粉碎过20目筛。
本发明第三方面提供所述的降低猪血脂的饲料预混剂的应用,将所述的饲料预混剂按照基础日粮的4wt%加入到生长育肥猪(60kg-出栏)的基础日粮中,用于降低血脂。
优选地,将所述的饲料预混剂按照基础日粮的4wt%加入到生长育肥猪(60kg-出栏)的基础日粮中,用于降低血清总胆固醇、甘油三酯和低密度脂蛋白胆固醇的含量,增加高密度脂蛋白胆固醇的含量。
本发明中,通过各组分之间协同作用,降低血脂。一方面通过苜蓿纤维产生的饱感,减少食物摄入,碳水化合物及脂肪摄入的减少,通过合成胆酸和脂肪酶的作用分解代谢脂肪,亚油酸抑制胆固醇的增加,同时使用黑木耳增加血管弹性,疏通血管,通过谷氨酸钠在肠道后端生成大量丁酸降低血脂。
与现有技术相比,本发明的预混剂原料容易获得,相对于使用药物控制血脂含量,本预混剂通过功能性营养降低体内血脂,安全无副作用。另外,对于人类常常担心血脂增高引起的健康问题,本发明也能够为人们通过饮食来调整血脂水平提供参考。
具体实施方式
一种降低猪血脂的饲料预混剂,每100重量份饲料预混剂份包括以下重量份含量的组分:
下面结合具体实施例对本发明进行详细说明。
实施例
本实施例降低猪血脂的饲料预混剂,按照表1中各组分的重量份配比,制备六个组别的饲料预混剂,分别记为预混剂组1~预混剂组6。
上述饲料预混剂采用以下方法制备得到:
(1)按配比称取苜蓿、亚油酸、黑木耳、合成胆酸、脂肪酶、谷氨酸钠和载体;
(2)将苜蓿及黑木耳干燥后粉碎,然后与亚油酸、合成胆酸、脂肪酶、谷氨酸钠和载体混合均匀,得到所述的降低猪血脂的饲料预混剂。
表1
预混剂组1 | 预混剂组2 | 预混剂组3 | 预混剂组4 | 预混剂组5 | 预混剂组6 | |
苜蓿 | 30 | 35 | 40 | 45 | 40 | 45 |
亚油酸 | 3 | 4 | 5 | 8 | 5 | 8 |
黑木耳 | 6 | 8 | 10 | 12 | 10 | 10 |
合成胆酸 | 3 | 4 | 5 | 8 | 0 | 5 |
脂肪酶 | 3 | 4 | 5 | 8 | 5 | 5 |
谷氨酸钠 | 5 | 8 | 10 | 15 | 10 | 0 |
玉米芯载体 | 50 | 37 | 25 | 4 | 30 | 27 |
合计 | 100 | 100 | 100 | 100 | 100 | 100 |
饲喂试验
选取健康、体重相近的宁乡花猪(120±7.68kg)70只。仔猪随机分在7个处理组:分别饲喂基础日粮(湖南傲农生物科技有限公司生产的854T,对照组)、基础日粮+4wt%预混剂组1(实验组1)、基础日粮+4w%预混剂组2(实验组2),基础日粮+4w%预混剂组3(实验组3),基础日粮+4w%预混剂组4(实验组4),基础日粮+4w%预混剂组5(实验组5),基础日粮+4w%预混剂组6(实验组6),每组10头猪。自由采食,自由饮水。所有实验猪饲养到250天左右时采血。前腔静脉采血10ml,将收集到的血液样本静置1小时,然后在4℃条件下,使用3000×g的离心速度对血液样本离心,离心时间为30分钟。收集上层血清。使用Determiner-L TCII,Determiner-L TG,Determiner-L HDL-C和Determiner-L LDL-C(Kyowa Medex,Japan)诊断试剂盒对血清总胆固醇(TC),甘油三酯(TG),高密度脂蛋白胆固醇(HDL)和低密度脂蛋白胆固醇(LDL)进行处理,在AU5421全自动生化分析仪平台上(美国Backman-kelt)进行分析。
试验结果参见表2。
表2单位:mmol/L
总表2的试验结果可以看出,实验组3的效果最好,总胆固醇、甘油三酯和低密度脂蛋白胆固醇显著低于对照组,高密度脂蛋白胆固醇显著高于对照组。
上述对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (10)
5.根据权利要求1所述的一种降低猪血脂的饲料预混剂,其特征在于,所述的载体为玉米芯载体。
6.如权利要求1~5任一所述的降低猪血脂的饲料预混剂的制备方法,其特征在于,包括以下步骤:
(1)按配比称取苜蓿、亚油酸、黑木耳、合成胆酸、脂肪酶、谷氨酸钠和载体;
(2)将苜蓿及黑木耳干燥后粉碎,然后与亚油酸、合成胆酸、脂肪酶、谷氨酸钠和载体混合均匀,得到所述的降低猪血脂的饲料预混剂。
7.根据权利要求6所述的降低猪血脂的饲料预混剂的制备方法,其特征在于,苜蓿及黑木耳干燥后粉碎过20目筛。
8.如权利要求1~5任一所述的降低猪血脂的饲料预混剂的应用,其特征在于,将所述的饲料预混剂按照基础日粮的4wt%加入到生长育肥猪的基础日粮中,用于降低血脂。
9.根据权利要求8所述的降低猪血脂的饲料预混剂的应用,其特征在于,将所述的饲料预混剂按照基础日粮的4wt%加入到生长育肥猪的基础日粮中,用于降低血清总胆固醇、甘油三酯和低密度脂蛋白胆固醇的含量,增加高密度脂蛋白胆固醇的含量。
10.根据权利要求8所述的降低猪血脂的饲料预混剂的应用,其特征在于,所述的基础日粮为湖南傲农生物科技有限公司生产的854T。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010976984.2A CN112136979A (zh) | 2020-09-17 | 2020-09-17 | 一种降低猪血脂的饲料预混剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010976984.2A CN112136979A (zh) | 2020-09-17 | 2020-09-17 | 一种降低猪血脂的饲料预混剂及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112136979A true CN112136979A (zh) | 2020-12-29 |
Family
ID=73893988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010976984.2A Pending CN112136979A (zh) | 2020-09-17 | 2020-09-17 | 一种降低猪血脂的饲料预混剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112136979A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102154237A (zh) * | 2011-01-04 | 2011-08-17 | 深圳市绿微康生物工程有限公司 | 一种有效降低动物体内胆固醇、血脂水平的脂肪酶及其应用 |
CN106234797A (zh) * | 2016-05-24 | 2016-12-21 | 河南农业大学 | 一种生产高亚麻酸、亚油酸猪肉的牧草饲粮 |
CN106689733A (zh) * | 2016-08-29 | 2017-05-24 | 南昌傲农生物科技有限公司 | 一种提高生长育肥猪采食量的预混剂及其制备方法 |
-
2020
- 2020-09-17 CN CN202010976984.2A patent/CN112136979A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102154237A (zh) * | 2011-01-04 | 2011-08-17 | 深圳市绿微康生物工程有限公司 | 一种有效降低动物体内胆固醇、血脂水平的脂肪酶及其应用 |
CN106234797A (zh) * | 2016-05-24 | 2016-12-21 | 河南农业大学 | 一种生产高亚麻酸、亚油酸猪肉的牧草饲粮 |
CN106689733A (zh) * | 2016-08-29 | 2017-05-24 | 南昌傲农生物科技有限公司 | 一种提高生长育肥猪采食量的预混剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114250179A (zh) | 一种具有减肥功效的微生物组合及其应用 | |
CN111164201B (zh) | 用于改善代谢症候群的副干酪乳杆菌gks6、其用途、医药组合物及可食用组合物 | |
Ayman et al. | Dietary chitosan oligosaccharides improves health status in broilers for safe poultry meat production | |
CN115192674A (zh) | 用于改善受试者的脂代谢作用的组合物和方法 | |
Kairalla et al. | Effect of diet supplemented with graded levels of ginger (Zingiber officinale) powder on growth performance, hematological parameters, and serum lipids of broiler chickens | |
Fitroh et al. | The use 3 of banana peel meal (Musa paradisiaca) as substitution of corn in the diets on performance and carcass production of hybrid ducks | |
CN112603953A (zh) | 一种减肥降脂外用组合物及其制备方法 | |
CN112136979A (zh) | 一种降低猪血脂的饲料预混剂及其制备方法和应用 | |
CN101912407B (zh) | 一种减肥降脂组合物 | |
CN109965290B (zh) | 改善肠道菌群代餐粉及其应用 | |
CN114514967A (zh) | 一种含有结构油脂opo的鱼饲料及其制备方法和应用 | |
CN111713666B (zh) | 一种减脂组合物及其制备方法 | |
CN111280453B (zh) | 一种牛樟芝水不溶性膳食纤维的制备方法 | |
CN1764463A (zh) | 降低血中低分子量含氮化合物浓度的改善病情用食品 | |
CN1853656A (zh) | 具有免疫调节作用的发酵组合物 | |
CN113693172A (zh) | 酿酒酵母在缓解运输应激所致鸡肉品质下降中的应用 | |
CN110123824B (zh) | 毛冬青皂苷a1的新用途 | |
CN105454601A (zh) | 黑青稞减肥茶(奶茶) | |
Ghavidel-Heydari et al. | The Effect of Fermented Sesame Meal or its Combination with Probiotics on the Performance, Carcass Triats, Blood Parameters, and Humoral Immunity in Growing Japanese Quails. | |
CN1871015A (zh) | 免疫调节性寡糖 | |
CN110477398A (zh) | 壳聚糖在制备抗肥胖食品中的应用 | |
CN105941836A (zh) | 一种乳酸菌发酵型液体鱼饲料的制备方法 | |
RU2378940C2 (ru) | Биологически активная добавка к пище | |
CN115777949B (zh) | 一种基于肠道菌群肠型特征的膳食纤维组合物及其制备方法与应用 | |
CN115414408B (zh) | 一种菊芋降血脂组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201229 |